Yeji

$TLSA

Tiziana Life Sciences Ltd

NasdaqMarket cap: —CIK 0001723069

Upcoming catalysts

0 surfaced

No catalysts surfaced for TLSA yet.

Drug pipeline

Milciclib Dose: 150 mg/day Mode of administration: oral
NSCLC
Placebo
Safety
Foralumab TZLS-401 100 µg
Non-Active Secondary Progressive Multiple Sclerosis
Foralumab TZLS-401 50 µg
Non-Active Secondary Progressive Multiple Sclerosis
Milciclib maleate
Hepatocellular Carcinoma
Foralumab Nasal
Multiple System Atrophy
Intranasal Foralumab Solution
Primary Progressive Multiple Sclerosis
Foralumab
Crohn's Disease

Recent & active trials

NCTDrugPhaseStatusPrimary completion
NCT06868628Foralumab NasalPhase 2Recruiting2027-04-01
NCT06890923Foralumab TZLS-401 100 µgPhase 2Recruiting2026-04-30
NCT06292923ForalumabPhase 2Recruiting2025-11-01
NCT05651269Milciclib Dose: 150 mg/day Mode of administration: oralPhase 2Unknown2024-12-01
NCT05028946ForalumabPhase 1Withdrawn2023-07-07
NCT05029609Intranasal Foralumab SolutionPhase 1Withdrawn2022-11-01
NCT04983446ForalumabPhase 2Withdrawn2022-10-30
NCT06879067PlaceboPhase 1Completed2019-07-23
NCT03109886Milciclib maleatePhase 2Completed2019-05-16
NCT03291249ForalumabPhase 2Withdrawn2018-12-01
NCT01011439Milciclib maleatePhase 2Terminated2017-05-31
NCT01301391Milciclib maleatePhase 2Terminated2017-05-31
NCT06802328Foralumab TZLS-401 50 µg—Available—